The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.

Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Xia(Guiyang Medical University), Jianhui Huang(China Geological Survey), Cong Luo(Central South University), Yonghui Wang(Lishui Central Hospital), Li Chen(University of Macau), Wenting Li(Wuhan University), Qi Xu(China Jiliang University), Lei Zhang(Wannan Medical College), Yanru Xie(Lishui Central Hospital), Jing‐Jing Li(Shanghai Institute of Nutrition and Health)
Journal of Clinical Oncology
June 1, 2024
10.1200/jco.2024.42.16_suppl.4095
Cited by 5

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
DeePMD-kit v2: A software package for deep potential models
|The Journal of Chemical Physics|2023|526
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412